Peter Lacamera, MD
Pulmonary Disease · Boston, MANPI 1124061759
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,607 of the $9,642 with a category attached, or 99.6%. F. Hoffmann-la Roche AG accounts for 81.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $7,838 and has fallen 81.7% since, to $1,438 in 2023.
Across 8 payments — averaging $1205.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$8K
- Boehringer Ingelheim$2K
- United Therapeutics Corporation$18
- Pfizer$17
Across 135 payments — averaging $9607.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$1.1M
- E.r. Squibb & Sons, L.L.C.$217K
- Boehringer Ingelheim International GmbH$17K
What the payments were for
- Speaking & faculty fees$9,607100%
- Food & beverage$170%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 4 | $7,822 |
| Boehringer Ingelheim | 2 | $1,785 |
| United Therapeutics Corporation | 1 | $18 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,642 in reported general payments places this provider in the 85th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 58 | $776,504 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 387 | $298,267 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 101 | $56,781 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $29,712 |
| Incruse ElliptaUmeclidinium Bromide | 64 | $27,605 |
| Spiriva HandihalerTiotropium Bromide | 19 | $13,667 |
| Arnuity ElliptaFluticasone Furoate | 48 | $12,006 |
| Spiriva RespimatTiotropium Bromide | 23 | $11,998 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $8,446 |
| Wixela InhubFluticasone Propion/Salmeterol | 48 | $7,479 |
| Serevent DiskusSalmeterol Xinafoate | 18 | $7,243 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 271 | $6,839 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $5,538 |
| Ventolin HfaAlbuterol Sulfate | 87 | $5,305 |
| Varenicline Tartrate | 14 | $5,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $1,785 | $788,50281 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.